News

During my residency training at Harvard’s McLean Hospital from 1956-1959, the treatment of choice for all of our patients was intensive psychodynamic psychotherapy.

Results from a study published in the Journal of Psychopharmacology suggest that MDMA combined with psychotherapy may be a safe and effective treatment for symptoms of post-traumatic stress disorder.

The DSM-5 Work Group that first suggested the inclusion of “Psychosis Risk Syndrome” has halfway come to its senses. It has dropped this stigmatizing name in a last ditch repackaging effort to salvage the proposal.

With the availability of drugs for ADHD and Alzheimer disease, more and more healthy people who have no mental health condition have been asking their psychiatrist to prescribe neuroenhancing medications in the hopes of improving their memory, cognitive focus, or attention span. What's an appropriate response when one of your patients asks for a prescription for a drug for this off-label purpose? 

We've asked our editorial board members to nominate recent articles that they believe are of critical importance to psychiatrists. And we've asked them to summarize key study findings-and what they may mean for your practice-in short (5 to 10 minute) podcasts.